Pretreatment Thrombocytosis as a Prognostic Factor in Women with Gynecologic Malignancies: a Meta-analysis

Min Yu1*, Lei Liu1*, Bing-Lan Zhang1*, Qi Chen1*, Xue-Lei Ma1, Yu-Ke Wu1, Chun-Shui Liang1, Zhi-Min Niu1, Xin Qin1, Ting Niu2*

Abstract

Background: This study was performed to analyze the prognostic implications of pretreatment or preoperative thrombocytosis in women with gynecologic malignancies. Material and Methods: We surveyed 2 medical databases, PubMed and EMBASE, to identify all relevant studies. A total of 14 (n=3,490) that evaluated the link between thrombocytosis and 5-year survival were included. REVMAN version 5.1 was used for our analysis and publication bias was evaluated using the Begg’s funnel plot and tested by STATA 11.0. Risk ratios (RRs) with 95% confidence intervals (CIs) generated by the random effect model were used to assess the strength of any association. Results: 709(20.3%) of the 3,490 patients exhibited thrombocytosis (platelet counts >400×10^9/L) at primary diagnosis, and their mortality was 1.62-fold higher compared with the others (RR=1.62, 95% CI= [1.28-2.05], p<0.0001). Thrombocytosis failed to have a stronger effect on the survival of advanced patients of stages III to IV in our study (n=478, RR=1.29, 95% CI= [1.13-1.48], p=0.0003), nor in women with cervical cancer in stage IB (n=1371, RR=1.73, 95% CI= [1.71-2.58], p=0.007). In addition, when adjusted for different carcinoma, it was associated with worse prognosis for all except the ones with vulvar cancer (n=201, RR= 0.43, 95% CI= [0.14-1.29], p=0.13). Conclusions: This meta-analysis indicated that thrombocytosis might be associated with a worse prognosis for patients with gynecologic malignancies but without specificity or sensitivity for the ones in advanced stage. When adjusted for different gynecologic malignancies, it showed a significant effect on survival of all except vulvar cancers.

Keywords: Thrombocytosis - gynecologic malignancies - meta-analysis - prognosis

Asian Pacific J Cancer Prev, 13 (12), 6077-6081

Introduction

The clinical observation of thrombocytosis (defined as a platelet counts >400×10^9/L) and malignancies was described over a century ago (Trousseau et al., 1867; Riess et al., 1872). According to the experimental evidence, it suggested that platelets actively promote cancer cell dissemination by protection of circulating cancer cells from immune surveillance, negotiation of cancer-cell arrest in the microvasculature, and stimulation of angiogenesis (Nieswandt et al., 1999; Borsig et al., 2008). Recent studies have addressed the prevalence and prognostic impact of thrombocytosis in various malignancies, including stomach, lung, kidney, uterus, and gynecologic malignancies (Zeimet et al., 1998; Menczer et al., 1998; Tomita et al., 2008; Heras et al., 2010; Cho et al., 2011). However, up to now, there was no meta-analysis comprehensively analyzing the prognostic value of thrombocytosis in cancer patients. The aim of this study was to comprehensively and quantitatively summarize the evidence for the use of pretreatment or preoperative thrombocytosis to evaluate its prognostic value for women with gynecologic malignancies.

Materials and Methods

Identification and Eligibility of Relevant Studies

We identified all studies, published or not, respectively targeting all thrombocytosis in patients with gynecologic malignancies, by an electronic search using online PubMed (MEDLINE) and EMBASE, with the search strategies based on combinations of “ovarian carcinoma”, “endometrial carcinoma”, “cervical carcinoma”, “vulvar carcinoma”, “platelet count”, “thrombocytosis” and “prognosis”. Last query was updated on April 6, 2012. References of retrieved articles were also screened to find out any studies missed by the search strategies.

After reading by two independent reviewers (Yu M. and Ma XL.), the candidate articles were identified for the meta-analysis studies based on title and abstract. Full-text review (Liang CS.) was retrieved when it cannot be categorized and abstract review was restricted to English, and the full-texts not in English were excluded. Reported data required for meta-analysis were then identified. Prespecified quality-related inclusion or exclusion criteria were not used and each study had not been weight by a quality score because no such score had received general

1Department of Cancer Center, State Key Laboratory of Biotherapy, 2Department of Hematology, West China Hospital, Sichuan University, Chengdu, China *Equal contributors *For correspondence: liuleihx@gmail.com, tingniu1@sina.com
agreement for meta-analyses of observational studies (Altman et al., 2001). We made an effort to contact investigators by e-mail to get unpublished data regarding thrombocytosis, gynecologic malignancies and survival.

Definitions and Standardizations

We defined thrombocytosis as platelet counts >400x10^9/L in patients with gynecologic malignancies. For statistical analysis, the value of 400x10^9 was used as a cut-off to separate the patients with high versus low platelet count, while the others did not mention.

The main reported data required for our meta-analysis was 5-year overall survival (OS). All of these patients were followed up until death or for at least 60 months. We also listed age, tumor location, number of patients got thrombocytosis, clinical stage and p values.

Data Extraction

Two reviewers (Yu M. and Liu L.) independently extracted data from all primary studies. In particular, we recorded each report using a standardized data collection form, with the following items: year of publication, the first author, country of origin, tumor location, number of patients analyzed, number of patients got thrombocytosis, mean or median age, clinical stage, p value, number of events in, OS or cumulative survival and survival curves. Disagreements were also resolved by consensus between the two reviewers, and studies were all retrospective.

Statistical Analyses

REVMAN, version 5.1 was used for our analysis and publication bias was evaluated using the Begg's funnel plot and tested by STATA 11.0 (STATA Corporation, College Station, TX) (Yu M., Niu ZM. and Wu YK.). A plot and tested by STATA 11.0 (STATA Corporation, College Station, TX) (Yu M., Niu ZM. and Wu YK.). A study was considered significant when the p value was less than 0.05 in univariate analysis. For the quantitative study was considered significant when the p value was less than 0.05 in univariate analysis. For the quantitative reverse relationship between 5-year overall survival and thrombocytosis, that is positive studies (Hernandez et al., 1992; Lopes et al., 1994; Rodriguez et al., 1994; Gücer et al., 1998; De Jonge et al., 1999; Scholz et al., 2000; Tamussino et al., 2001; Kuyumcuoglu et al., 2010).

Finally, 14 studies (n=3490 patients) were eligible for the meta-analysis, and 12 of the 14 reports found an inverse relationship between 5-year overall survival and thrombocytosis, that is positive studies (Hernandez et al., 1992; Lopes et al., 1994; Rodriguez et al., 1994; Gücer et al., 1998; De Jonge et al., 1999; Scholz et al., 2000; Tamussino et al., 2001; Kuyumcuoglu et al., 2010).

Table 1. Characteristics of the Eligible Studies

<table>
<thead>
<tr>
<th>year</th>
<th>author</th>
<th>country</th>
<th>location</th>
<th>No. of thrombocytosis</th>
<th>clinical stage</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1992</td>
<td>Hernandez</td>
<td>U.S.</td>
<td>cervix</td>
<td>113</td>
<td>I-IV</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>1994</td>
<td>Rodriguez</td>
<td>U.S.</td>
<td>cervix</td>
<td>219</td>
<td>IB</td>
<td>NR</td>
</tr>
<tr>
<td>1994</td>
<td>Lopes*</td>
<td>England</td>
<td>cervix</td>
<td>643</td>
<td>I-IV</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>1994</td>
<td>Lopes*</td>
<td>England</td>
<td>cervix</td>
<td>436</td>
<td>IB</td>
<td>NS</td>
</tr>
<tr>
<td>1994</td>
<td>Lopes*</td>
<td>England</td>
<td>cervix</td>
<td>65</td>
<td>III-IV</td>
<td>NS</td>
</tr>
<tr>
<td>1994</td>
<td>Hernandez</td>
<td>U.S.</td>
<td>cervix</td>
<td>623</td>
<td>IB</td>
<td>0.4</td>
</tr>
<tr>
<td>1999</td>
<td>De Jonge</td>
<td>Norway</td>
<td>cervix</td>
<td>93</td>
<td>IB</td>
<td>0.0012</td>
</tr>
<tr>
<td>1999</td>
<td>Ofer Lavie</td>
<td>England</td>
<td>vulva</td>
<td>201</td>
<td>I-IV</td>
<td>0.586</td>
</tr>
<tr>
<td>1998</td>
<td>Fatih Gücer</td>
<td>Turkey</td>
<td>endometrium</td>
<td>135</td>
<td>I-IV</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>2000</td>
<td>Scholz</td>
<td>Austria</td>
<td>endometrium</td>
<td>59</td>
<td>III-IV</td>
<td>0.035</td>
</tr>
<tr>
<td>2009</td>
<td>Gorelick</td>
<td>U.S.</td>
<td>endometrium</td>
<td>29</td>
<td>III-IV</td>
<td>0.015</td>
</tr>
<tr>
<td>2004</td>
<td>Li</td>
<td>U.S.</td>
<td>ovary</td>
<td>146</td>
<td>III-IV</td>
<td>&lt;0.0004</td>
</tr>
<tr>
<td>2009</td>
<td>Gungor</td>
<td>Turkey</td>
<td>ovary</td>
<td>292</td>
<td>I-IV</td>
<td>&lt;0.0004</td>
</tr>
<tr>
<td>2011</td>
<td>Maria Lee</td>
<td>Korea</td>
<td>ovary</td>
<td>179</td>
<td>III-IV</td>
<td>0.005</td>
</tr>
<tr>
<td>2012</td>
<td>Stone</td>
<td>U.S.</td>
<td>ovary</td>
<td>619</td>
<td>I-IV</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>2012</td>
<td>Jian Qiu</td>
<td>China</td>
<td>ovary</td>
<td>139</td>
<td>I-IV</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

*they were from the same study; NR, not reported; NS, no significant
publication biases were found in results of meta-analyses was used to evaluate publication bias. No significant publication biases were found in results of meta-analyses.

Thrombocytosis was associated with worse prognosis regarding the risk of death within 5 years. As between-study heterogeneity was significant (I²>50%, p<0.0001), random model was used. Mortality was 1.62-fold higher in patients with thrombocytosis compared to the others with normal platelet count (n=3490, RR=1.62, 95% CI= [1.28-2.05], p<0.0001; Figure 1). Begg’s test and funnel was used to evaluate publication bias. No significant publication biases were found in results of meta-analyses.

Meta-analysis: 5-year overall survival
Thrombocytosis was associated with worse prognosis regarding the risk of death within 5 years. As between-study heterogeneity was significant (I²>50%, p<0.0001), random model was used. Mortality was 1.62-fold higher in patients with thrombocytosis compared to the others with normal platelet count (n=3490, RR=1.62, 95% CI= [1.28-2.05], p<0.0001; Figure 1). Begg’s test and funnel was used to evaluate publication bias. No significant publication biases were found in results of meta-analyses.
Figure 4. A. Meta-analysis of the association between thrombocytosis and the risk of death at 5 years for patients with cervical cancer. B. Meta-analysis of the association between thrombocytosis and the risk of death at 5 years for patients with ovarian cancer. C. Meta-analysis of the association between thrombocytosis and the risk of death at 5 years for patients with endometrial cancer. D. Meta-analysis of the association between thrombocytosis and the risk of death at 5 years for patients with cervical cancer in stage IB. Each study is shown by the name of the lead author and the RR with 95% CIs. The summary RR and 95% CIs (according to random effect calculations) are also shown.

Discussion

There has been great interest in identifying prognostic markers for patients with gynecologic malignancies as these markers can help guide clinical decision-making regarding therapy and outcomes. In this paper, we examined the correlation of thrombocytosis (platelet counts >400x10^9/L) with OS before any curative treatment or surgery of gynecologic malignancies. Our meta-analysis for the 14 primary studies from the published literature according to the survival data in patients with gynecologic malignancies, showed that the thrombocytosis (platelet counts >400x10^9/L) at primary diagnosis is associated with worse overall survival (RR=1.62) and proved to be a significant but weaker prognostic factor for patients in stage III to IV in comparison with the entire group (RR=1.29), although it had evidence that thrombocytosis is more frequent in advanced disease in patients with ovarian cancer, endometrial cancer and cervical cancer (Gücer et al., 1998; Gücer et al., 2004; Gorelick et al., 2009). For the cervical cancer patients in stage IB, especially, it showed a significant effect on the survival too (RR=1.73). When adjusted for different gynecologic malignancies, all three of the meta-analyses for endometrial cancer (RR=2.09), cervical cancer (RR=1.86) and ovarian cancer (RR=1.52) gave statistically significant results, favoring a link between thrombocytosis and poor survival, while the vulvar cancer did not (RR=0.43).

Our findings were consistent with the outcome on the link between thrombocytosis and survival in patients with another common cancer for women, breast cancer, which showed an incidence of 3.7% (161/4300) and a strong relation (n=4300, RR=2.04, 95% CI=[1.43-2.92], p<0.0001) (Taucher et al., 2003). We finally got the only study about breast cancer and it got the maximum sample size (n=4300). To avoid bias, four malignancies were ultimately included in our study, as endometrial, cervical, ovarian and vulvar cancer. However, only one study had evaluated the correlation between thrombocytosis and survival for patients with vulva cancer, and reported that thrombocytosis had no effect on 5-year survival rate in 201 patients with primarily surgical treatment (Lavie et al., 1999). Compared to the others, the studies about prognosis of patients with ovarian cancer lagged behind (2004-2012), and the earliest studies were all about cervical cancer (1992-1999). The overall statistical link we got between thrombocytosis and survival was rather weak, with a global RR of 1.62. While as a rule of the thumb, a prognostic factor with a RR <2 is of limited practical use (Hayes et al., 2001), only the breast and endometrial cancer subgroup got a RR>2.

There were no studies which had analyzed the prognostic value of thrombocytosis in tumors yet, and thrombocytosis has repeatedly been identified as a marker of gynecologic malignancies with independent prognostic value. Our study aimed to summarize the evidence for the use of pretreatment or preoperative thrombocytosis to evaluate its prognostic value for women with gynecologic malignancies. According to the International Federation of Gynecologists and Obstetricians (FIGO) guidelines, all patients had received surgery, on the basis of primary surgical staging with the intent of optimal tumor cytoreduction, radiotherapy or chemotherapy.

The precise mechanisms underlying the cancer-associated thrombocytosis are not clearly understood. Although the thrombocytosis should not be thought of as an isolated factor involved in the cancer growth and metastatic process, it might represents an important therapeutic prospect. For example, heparin given as thromboembolic prophylaxis in the perioperative period may incidentally act to reduce the assistance of platelets to tumor spread (Nash et al., 2002). However, it could also results in a lowering of the platelet count by administration of cytotoxic drugs in chemotherapy and is currently unclear whether decreasing platelet counts has a place in the treatment of malignant disease.

Though we attempted to minimize publication bias by searching completely, it is unavoidable that some data was missing for various reasons such as publishing language only in German (Zeimet et al., 1993), failing to get the survival data in the full-text or the authors (Zeimet et al., 1994; Menczer et al., 1998; Hernandez et al., 2000; Tamussino et al., 2001; Kuyumcuoglu et al., 2010), or unpublished or ignored studies. All of our studies are retrospective observational studies, which are more prone to many biases than prospective randomized controlled studies (Grimes et al., 2002). Between-study heterogeneity is significant in our study, but we tried to reduce the variability by screening the literature using the same standard, such as the same experimental design and definition of thrombocytosis in prognostic meta-analysis. Furthermore, results should be interpreted with caution.
Pretreatment Thrombocytosis as a Prognostic Factor in Women with Gynecologic Malignancies: a Meta-analysis

DOI:http://dx.doi.org/10.7314/APJCP.2012.13.12.6077

for the probable contribution of the clinical stage, age, pathology and location to its prognostic effect.

On the basis of the results of this analysis, we believe that the thrombocytosis is associated with worse prognosis for patients with gynecologic malignancies but do not have specificity or sensitivity for a variety of staging. When adjusted for different gynecologic malignancies, it showed a significant effect on survival except the vulvar cancer. Although briefly discussed in one study (Lavie et al., 1999), additional investigations evaluating thrombocytosis as a marker of vulva cancer progression or response to therapy would be a valuable addition to the literature. In the interim, this meta-analysis appears to initially support the hypothesis that thrombocytosis is associated with a reduced probability of overall survival from gynecologic malignancies.

Acknowledgements

The authors declare that they have no competing interests.

References


